NASDAQ:ENTX Entera Bio (ENTX) Stock Forecast, Price & News $0.82 +0.01 (+1.24%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$0.81▼$0.8850-Day Range$0.68▼$1.1652-Week Range$0.47▼$2.12Volume5,173 shsAverage Volume158,950 shsMarket Capitalization$23.47 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Entera Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside820.1% Upside$7.50 Price TargetShort InterestHealthy0.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$30,300 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.31) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector530th out of 986 stocksBiological Products, Except Diagnostic Industry85th out of 160 stocks 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Entera Bio has a forecasted upside of 820.1% from its current price of $0.82.Amount of Analyst CoverageEntera Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.17% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently decreased by 23.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Entera Bio this week, compared to 1 article on an average week.Search Interest11 people have searched for ENTX on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,300.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.15% of the stock of Entera Bio is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of Entera Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.31) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Entera Bio (NASDAQ:ENTX) StockEntera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.Read More Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Stock News HeadlinesJune 7, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of DirectorsJune 7, 2023 | technews.tmcnet.comEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of DirectorsJune 8, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 12, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Entera Bio Ltd. Issued By HC Wainwright (NASDAQ:ENTX)May 7, 2023 | finance.yahoo.comEntera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)May 6, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Q1 2023 Financial Results and Corporate UpdatesMay 5, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2023 | msn.comEntera Bio: Q1 Earnings InsightsJune 8, 2023 | UNKNOWN (Ad)This Company Is Solving A Multi-Billion Dollar Problem!This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!May 5, 2023 | finance.yahoo.comEntera Bio Announces Q1 2023 Financial Results and Corporate UpdatesMay 3, 2023 | technews.tmcnet.comEntera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and TherapeuticsMay 3, 2023 | finance.yahoo.comEntera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and TherapeuticsMay 1, 2023 | americanbankingnews.comEntera Bio (NASDAQ:ENTX) vs. Immunovant (NASDAQ:IMVT) Financial ComparisonApril 27, 2023 | marketwatch.comMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory BoardApril 26, 2023 | finance.yahoo.comMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory BoardApril 8, 2023 | americanbankingnews.comMiranda Jayne Toledano Buys 30,000 Shares of Entera Bio Ltd. (NASDAQ:ENTX) StockApril 8, 2023 | americanbankingnews.comEntera Bio Ltd. Expected to Post Q1 2023 Earnings of ($0.12) Per Share (NASDAQ:ENTX)April 7, 2023 | americanbankingnews.comEntera Bio Ltd. Expected to Post Q1 2024 Earnings of ($0.23) Per Share (NASDAQ:ENTX)April 6, 2023 | americanbankingnews.comEntera Bio (NASDAQ:ENTX) Rating Reiterated by HC WainwrightApril 4, 2023 | msn.comHC Wainwright & Co. Reiterates Entera Bio (ENTX) Buy RecommendationApril 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)April 3, 2023 | finance.yahoo.comEntera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal ProgramApril 1, 2023 | americanbankingnews.comEntera Bio (NASDAQ:ENTX) Stock Rating Reaffirmed by HC WainwrightMarch 31, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2023 | finance.yahoo.comEntera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022March 23, 2023 | finance.yahoo.comEntera Bio Regains Compliance with Nasdaq Listing RequirementsMarch 10, 2023 | finance.yahoo.comWill Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?See More Headlines ENTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTX Company Calendar Last Earnings3/31/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+820.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,070,000.00 Net Margins-9,754.48% Pretax Margin-17,171.21% Return on Equity-85.95% Return on Assets-77.34% Debt Debt-to-Equity RatioN/A Current Ratio7.61 Quick Ratio7.61 Sales & Book Value Annual Sales$130,000.00 Price / Sales180.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book1.99Miscellaneous Outstanding Shares28,800,000Free Float27,321,000Market Cap$23.47 million OptionableNot Optionable Beta1.82 Key ExecutivesMiranda J. ToledanoChief Executive Officer & DirectorHillel GalitzerChief Operating OfficerDana Yaacov GarbeliChief Financial OfficerGregory BurshteinVice President-Research & DevelopmentAnke HoppeVice President-Clinical OperationsKey CompetitorsAvalon GloboCareNASDAQ:ALBTAIM ImmunoTechNYSE:AIMAxcella HealthNASDAQ:AXLAInhibikase TherapeuticsNYSE:IKTHarpoon TherapeuticsNASDAQ:HARPView All CompetitorsInsidersMiranda Jayne ToledanoBought 30,000 shares on 4/4/2023Total: $30,300.00 ($1.01/share)Sean EllisBought 30,000 shares on 11/11/2022Total: $15,900.00 ($0.53/share)Miranda Jayne ToledanoBought 50,000 shares on 11/11/2022Total: $26,500.00 ($0.53/share)Sean EllisBought 14,900 shares on 7/21/2022Total: $24,436.00 ($1.64/share)View All Insider Transactions ENTX Stock - Frequently Asked Questions Should I buy or sell Entera Bio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTX shares. View ENTX analyst ratings or view top-rated stocks. What is Entera Bio's stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 820.1% from the stock's current price. View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts. How have ENTX shares performed in 2023? Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 11.7% and is now trading at $0.8151. View the best growth stocks for 2023 here. Are investors shorting Entera Bio? Entera Bio saw a decrease in short interest in May. As of May 15th, there was short interest totaling 37,600 shares, a decrease of 23.7% from the April 30th total of 49,300 shares. Based on an average daily trading volume, of 230,300 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the company are sold short. View Entera Bio's Short Interest. When is Entera Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ENTX earnings forecast. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) released its quarterly earnings data on Friday, March, 31st. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. Entera Bio had a negative trailing twelve-month return on equity of 85.95% and a negative net margin of 9,754.48%. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). When did Entera Bio IPO? (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager. What is Entera Bio's stock symbol? Entera Bio trades on the NASDAQ under the ticker symbol "ENTX." How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Entera Bio's stock price today? One share of ENTX stock can currently be purchased for approximately $0.82. How much money does Entera Bio make? Entera Bio (NASDAQ:ENTX) has a market capitalization of $23.47 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact Entera Bio? Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com. This page (NASDAQ:ENTX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.